Zoekresultaten voor

Fluctuations in anti-Müllerian hormone levels throughout the menstrual cycle parallel fluctuations in the antral follicle count: a cohort study. Auteurs: M. Depmann et al.Tijdschrift: Acta Obstet Gynecol Scand. 2016, Volume 95(7), 820-828. Background In this prospective cohort study we aimed to investigate the hypothesis that fluctuations in anti-Müllerian hormone levels stem from fluctuations in the … Continued

Comparative study of highly purified HMG versus recombinant FSH+recombinant LH in ovulation induction for intrauterine insemination: A randomized controlled trial. Auteurs: E. Labarta, E. BoschTijdschrift: Medicina Reproductiva y Embriología Clínica, Volume 3, Nummer 1, April 2016 Background This study sought to compare the ovarian response and follicular dynamics after stimulation with HP-hMG vs. rFSH + … Continued

Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Auteurs: P. Platteau, A. Nyboe Andersen, A. Balen, P. Devroey, P. Sørensen, L. Helmgaard, J.C. ArceTijdschrift: Human Reproduction, Volume 21, Nummer 7, Maart 2006 Background The contribution of the LH … Continued

Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Auteurs: R. Fleming et al. Tijdschrift: Reprod Biomed Online, 2015, Volume 31(4) , 486-96 Background Oocyte number and quality decline with age; however, fertility varies significantly even among women of the same age. Various measures have been developed to predict response to ovarian stimulation and reproductive … Continued

Low-dose human menopausal gonadotrophin versus clomiphene citrate in subfertile couples treated with intrauterine insemination: a randomized controlled trial. Auteurs: K. Peerear et al.Tijdschrift: Human Reproduction, Volume 30, Issue 5, Mei 2015 Background Can controlled ovarian stimulation with low-dose human menopausal gonadotrophin (hMG) improve the clinical pregnancy rate when compared with ovarian stimulation with clomiphene citrate … Continued

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Auteurs: S.M. Nelson et al.Tijdschrift: Fertil Steril. 2015, Volume 103(4), 923-930. Background To compare antimüllerian hormone (AMH) and antral follicle count (AFC) as predictors of ovarian … Continued

Testing and interpreting measures of ovarian reserve: a committee opinion. Auteurs: Practice Committee of the American Society for Reproductive MedicineTijdschrift: Fertil Steril. 2020, Volume 114(6), 1151-1157. Background Ovarian reserve is defined as the number of oocytes remaining in the ovary, or oocyte quantity (oocyte number). Markers of ovarian reserve include hormone levels and sonographically measured … Continued

Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Auteurs: F. Olivennes, G. Trew, A. Borini, F. Broekmans, P. Arriagada, D.W. Warne, C.M. HowlesTijdschrift: Reproductive BioMedicine Online, Volume 30, Issue 3, Maart 2015 Background In this randomized, controlled, open-label, phase IV study, ovarian response after a follitropin alfa starting dose determined … Continued

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis. Auteurs: J. Xiao et al.Tijdschrift: Fertility and Sterility, Volume 100, Issue 6, December 2013 Objective To evaluate the effectiveness of gonadotropin-releasing hormone (GnRH) antagonist in poor ovarian responders undergoing in vitro fertilization (IVF). Methods Design: Systematic … Continued

The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. Auteurs: Theodora C van Tilborg et al.Tijdschrift: BMC Women’s Health volume 12, Artikel 29, 2012 Background Costs of in vitro fertilisation (IVF) are high, which is partly due to the use of follicle stimulating hormone (FSH). … Continued